1
|
Pachón Olmos V, Pollán M, Fernández de Larrea-Baz N, Fernández-Morata J, Ruiz-Moreno E, García-Pérez J, Castelló A, Sierra MÁ, Lucas P, Alonso-Ledesma I, Stradella A, Cantos B, Ramón y Cajal T, Santisteban M, Seguí MÁ, Santaballa Bertrán A, Granja M, Camps-Herrero J, Recalde S, Mendez M, Calvo Verges N, Pérez-Gómez B, Pastor-Barriuso R, Lope V. Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer. Cancers (Basel) 2025; 17:708. [PMID: 40002301 PMCID: PMC11853811 DOI: 10.3390/cancers17040708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 02/14/2025] [Accepted: 02/18/2025] [Indexed: 02/27/2025] Open
Abstract
BACKGROUND/OBJECTIVES The 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations benefit primary prevention and survivor outcomes. This study evaluated the adherence to these recommendations during the year prior to breast cancer diagnosis and identified related clinical and sociodemographic factors. METHODS A total of 915 patients with breast cancer were recruited from eight hospitals in four regions of Spain. The participants completed an epidemiologic questionnaire and a food frequency questionnaire. The compliance with the WCRF/AICR recommendations was assessed using a standardized score based on seven recommendations. Standardized prevalences and standardized prevalence ratios (SPRs) for moderate and high adherence were calculated based on participant characteristics using binary and multinomial logistic regression models. RESULTS The mean adherence was 3.5 points out of 7. The recommendations with the best and worst adherence were avoiding sugar-sweetened drinks (54.4% adherence) and maintaining a fiber-rich diet (4.4% consumed ≥30 g/day). The overall adherence was better in women aged ≥60 years (SPR = 1.55; 95% CI = 1.09-2.22), and worse in those with a caloric intake ≥2000 kcal/day (SPR = 0.48; 95% CI = 0.37-0.62) or ≥2 comorbidities (SPR = 0.66; 95% CI = 0.49-0.89). The adherence to maintaining a healthy weight was worse in those with ≥2 comorbidities and stage III-IV tumors. The physical activity adherence was worse in working women and those with ≥2 comorbidities. The alcohol restriction adherence was worse in smokers. Younger women, smokers and those with a low calorie intake were less adherent to the fruit/vegetable recommendation. The consumption of fiber and limited consumption of red/processed meat adherence was poor in all the subgroups. The adherence to a limited consumption of fast food and sugary drinks was worse in younger women and high-calorie-diet consumers. CONCLUSIONS The differences in the adherence to recommendations according to patient characteristics justify the design of personalized interventions for breast cancer patients.
Collapse
Affiliation(s)
- Vanessa Pachón Olmos
- Preventive Medicine Department, La Paz-Carlos III-Cantoblanco University Hospital, Po de la Castellana 261, 28046 Madrid, Spain
| | - Marina Pollán
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Nerea Fernández de Larrea-Baz
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Julia Fernández-Morata
- Programa de Doctorado en Ciencias Biomédicas y Salud Pública IMIENS-UNED-ISCIII, Escuela Internacional de Doctorado de la Universidad Nacional de Educación a Distancia (EIDUNED), Avda. Monforte de Lemos 5, 28029 Madrid, Spain
| | - Emma Ruiz-Moreno
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Javier García-Pérez
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Adela Castelló
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - María Ángeles Sierra
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Pilar Lucas
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
| | - Isabel Alonso-Ledesma
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Agostina Stradella
- Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia, Idibell, Avinguda de la Granvia de l’Hospitalet, 199, 08908 L’Hospitalet de Llobregat, Spain
| | - Blanca Cantos
- Department of Medical Oncology, Hospital Universitario Puerta de Hierro, C. Joaquín Rodrigo, 1, 28222 Majadahonda, Spain
| | - Teresa Ramón y Cajal
- Consulta de Cáncer Familiar, Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, Horta-Guinardó, 08025 Barcelona, Spain
| | - Marta Santisteban
- Breast Cancer Unit, Department of Medical Oncology, Clínica Universidad de Navarra, IdiSNA, Av. de Pío XII, 36, 31008 Pamplona, Spain
| | - Miguel Ángel Seguí
- Department of Medical Oncology, Consorcio Hospital Universitario Parc Tauli, Parc Taulí, 1, 08208 Sabadell, Spain
| | - Ana Santaballa Bertrán
- Medical Oncology Department, La Fe Health Research Institute (IISLaFe), La Fe University Hospital, Avinguda de Fernando Abril Martorell, 106, Quatre Carreres, 46026 Valencia, Spain
| | - Mónica Granja
- Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Calle Prof Martín Lagos, S/N, Moncloa-Aravaca, 28040 Madrid, Spain
| | - Julia Camps-Herrero
- Department of Radiology, Hospital Universitario de La Ribera, Ctra. Corbera km 1, 46600 Alzira, Spain
| | - Sabela Recalde
- Multidisciplinary Breast Cancer Unit, Department of Medical Oncology, Institut Català d’Oncologia-Hospitalet, Avinguda de la Granvia de l’Hospitalet, 199, 08908 L’Hospitalet de Llobregat, Spain
| | - Miriam Mendez
- Department of Medical Oncology, Hospital Universitario Puerta de Hierro, C. Joaquín Rodrigo, 1, 28222 Majadahonda, Spain
| | - Nuria Calvo Verges
- Consulta de Cáncer Familiar, Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, Horta-Guinardó, 08025 Barcelona, Spain
| | - Beatriz Pérez-Gómez
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Roberto Pastor-Barriuso
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Virginia Lope
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III (ISCIII), Avda. Monforte de Lemos 5, 28029 Madrid, Spain (A.C.); (I.A.-L.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos 3-5, 28029 Madrid, Spain
| |
Collapse
|
2
|
Fama’ F, Sindoni A, Sun H, Kim HY, Geraci G, Colonna MR, Mazzeo C, Brenta G, Galeano M, Benvenga S, Dionigi G. Development of Histologically Verified Thyroid Diseases in Women Operated for Breast Cancer: A Review of the Literature and a Case Series. J Clin Med 2022; 11:3154. [PMID: 35683541 PMCID: PMC9181259 DOI: 10.3390/jcm11113154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 05/21/2022] [Accepted: 05/31/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The possible relationships between breast and thyroid diseases have been reported in the literature. The purpose of our study was to evaluate the occurrence of histologically verified thyroid pathologies in women who were diagnosed with breast cancer and, after mastectomy/quadrantectomy complemented by oncological treatment, were thyroidectomized based on their periodic thyroid evaluation. PATIENTS AND METHODS Our series consist of 31 women with a mean age of 62.9 ± 10.9 years (range, 45-81) treated for breast cancer (18 right-sided, 11 left-sided, and 2 bilateral), of whom 29 were thyroidectomized, since two women who developed Graves' disease refused thyroidectomy. These 31 women belong to a cohort of 889 women who referred to the Breast Surgery Unit of our university hospital during the period January 2010 through December 2020. RESULTS The mean time interval between breast cancer and thyroid pathologies was 48.1 ± 23.4 months (range, 12-95). The final diagnosis at histopathology was infiltrating ductal breast carcinoma in 26 women (with 2/26 patients having bilateral carcinoma) and infiltrating lobular breast carcinoma in the other 5 women. Ten of the twenty-nine thyroidectomized women (34.5%) had a thyroid malignancy on histology: five papillary carcinomas, three papillary micro-carcinomas and two follicular carcinomas. Two of the five women with papillary carcinoma also had histological evidence of chronic lymphocytic thyroiditis/Hashimoto's thyroiditis, which was also detected in another five women with benign thyroid diseases. CONCLUSIONS We suggest that breast cancer survivors should be made aware of the possible increased risk of thyroid pathologies (including thyroid malignancy) so that they can undergo screening and follow-up.
Collapse
Affiliation(s)
- Fausto Fama’
- Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University Hospital “G. Martino” of Messina, 98125 Messina, Italy; (M.R.C.); (C.M.); (M.G.)
| | - Alessandro Sindoni
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy;
- New Hospital of Prato S. Stefano, Azienda USL Toscana Centro, 59100 Prato, Italy
| | - Hui Sun
- Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Changchun 130033, China;
| | - Hoon Yub Kim
- Department of Surgery, KUMC Thyroid Center, Korea University Hospital, Korea University College of Medicine, Seoul 02841, Korea;
| | - Girolamo Geraci
- Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, 90100 Palermo, Italy;
| | - Michele Rosario Colonna
- Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University Hospital “G. Martino” of Messina, 98125 Messina, Italy; (M.R.C.); (C.M.); (M.G.)
| | - Carmelo Mazzeo
- Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University Hospital “G. Martino” of Messina, 98125 Messina, Italy; (M.R.C.); (C.M.); (M.G.)
| | - Gabriela Brenta
- Division of Endocrinology, Cesar Milstein Hospital, Buenos Aires C1221 ABE, Argentina;
| | - Mariarosaria Galeano
- Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University Hospital “G. Martino” of Messina, 98125 Messina, Italy; (M.R.C.); (C.M.); (M.G.)
| | - Salvatore Benvenga
- Department of Clinical and Experimental Medicine, University Hospital “G. Martino” of Messina, 98125 Messina, Italy;
| | - Gianlorenzo Dionigi
- Division of Surgery, Istituto Auxologico Italiano IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), 20122 Milan, Italy;
- Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
| |
Collapse
|
3
|
Yang H, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med 2020; 18:225. [PMID: 32838791 PMCID: PMC7446157 DOI: 10.1186/s12916-020-01690-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 06/30/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Despite the biological link between thyroid hormones and breast cancer cell proliferation shown in experimental studies, little is known about the association between hyperthyroidism and breast cancer, as well as its association with the most common mammographic and genetic risk predictors for breast cancer. METHODS This study estimates the incidence rate ratios (IRRs) of breast cancer among women diagnosed with hyperthyroidism, compared to those who are not, using two cohorts: a Swedish national cohort of the general female population (n = 3,793,492, 2002-2011) and the Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA, n = 69,598, 2002-2017). We used logistic regression to estimate the odds ratios (ORs) of hyperthyroidism according to the mammographic and genetic risk predictors for breast cancer. RESULTS An increased risk of breast cancer was observed in patients in the national cohort with hyperthyroidism (IRR = 1.23, 95% CI = 1.12-1.36), particularly for toxic nodular goiter (IRR = 1.38, 95% CI = 1.16-1.63). Hyperthyroidism was associated with higher body mass index, early age at first birth, and lower breastfeeding duration. Higher mammographic density was observed in women with toxic nodular goiter, compared to women without hyperthyroidism. Additionally, among genotyped women without breast cancer in the KARMA cohort (N = 11,991), hyperthyroidism was associated with a high polygenic risk score (PRS) for breast cancer overall (OR = 1.98, 95% CI = 1.09-3.60) and for estrogen receptor-positive specific PRS (OR = 1.90, 95% CI = 1.04-3.43). CONCLUSION Hyperthyroidism is associated with an increased risk of breast cancer, particularly for patients with toxic nodular goiter. The association could be explained by higher mammographic density among these women, as well as pleiotropic genetic variants determining shared hormonal/endocrine factors leading to the pathology of both diseases.
Collapse
Affiliation(s)
- Haomin Yang
- Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Xuefu North Road 1, University Town, Fuzhou, 350122 China
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Natalie Holowko
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Felix Grassmann
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
- Department of Oncology, South General Hospital, SE-11883 Stockholm, Sweden
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| |
Collapse
|